Franchise Capital’s BioNTech BNTX Stock Holding History

Franchise Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-43,650	Closed	-$6.51M	–	18
2022 Q2	$6.51M	Buy	+43,650	New	+$6.67M	2.18%	12

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Franchise Capital's BNTX Position: Q3 2022 in Review

Franchise Capital sold out of BioNTech (BNTX) in Q3 2022, closing a stake of 43,650 shares — an estimated $6.51M sold.

Franchise Capital first reported a position in BNTX in Q2 2022 and held it in 1 quarter. The position peaked at $6.51M in Q2 2022. 264 funds tracked by Wall St. Rank hold BNTX as of Q3 2022.

Franchise Capital reported no remaining BioNTech position as of Q3 2022 after selling out during the quarter.
Franchise Capital sold 43,650 BioNTech shares in Q3 2022, an estimated $6.51M.
Franchise Capital first reported a position in BioNTech in Q2 2022 and held it in 1 quarter.
Franchise Capital's BioNTech position peaked at $6.51M in Q2 2022.
264 funds tracked by Wall St. Rank held BioNTech as of Q3 2022.

Based on Franchise Capital's 13F filing for Q3 2022, filed 15 Nov 2022.